Objective: To evaluate the efficacy of methimazole combined with propranolol sustained-release tablets in the treatment of hyperthyroidism and its influence on FT4 and FT3 levels. Methods: Eighty-six hyperthyroidism p...Objective: To evaluate the efficacy of methimazole combined with propranolol sustained-release tablets in the treatment of hyperthyroidism and its influence on FT4 and FT3 levels. Methods: Eighty-six hyperthyroidism patients who are fully aware of the research content and voluntarily participate in the research were selected as the research samples. The first patient and the last patient were treated in our hospital in January 2021 and December 2021, respectively, and they were equally divided into two groups. There were two groups, one group was named as the control group, the other group was named as the observation group, and the treatment drug was methimazole combined with propranolol sustained-release tablets. Results: The indexes selected in the study were thyroid index, serum index, therapeutic effect and adverse reactions. The data obtained were analyzed and compared between groups, and the observation group was better than the control group (P 0.05). Conclusion: When treating patients with hyperthyroidism clinically, the scheme of methimazole combined with propranolol sustained-release tablets can not only effectively improve the thyroid index of patients, but also relieve their related symptoms, which has high clinical application value.展开更多
文摘Objective: To evaluate the efficacy of methimazole combined with propranolol sustained-release tablets in the treatment of hyperthyroidism and its influence on FT4 and FT3 levels. Methods: Eighty-six hyperthyroidism patients who are fully aware of the research content and voluntarily participate in the research were selected as the research samples. The first patient and the last patient were treated in our hospital in January 2021 and December 2021, respectively, and they were equally divided into two groups. There were two groups, one group was named as the control group, the other group was named as the observation group, and the treatment drug was methimazole combined with propranolol sustained-release tablets. Results: The indexes selected in the study were thyroid index, serum index, therapeutic effect and adverse reactions. The data obtained were analyzed and compared between groups, and the observation group was better than the control group (P 0.05). Conclusion: When treating patients with hyperthyroidism clinically, the scheme of methimazole combined with propranolol sustained-release tablets can not only effectively improve the thyroid index of patients, but also relieve their related symptoms, which has high clinical application value.
